The Adeno-associated virus recombinant AAV (rAAV) gene delivery system is entering a crucial and exciting phase with the promise of more than 20 years of intense research now realized in a number of successful human clinical trials. However, two major challenges that must be overcome for full realization are transient or low transgene expression and the detrimental effect of circulating host antibodies. The primary goal of our research is to use structural biology approaches, combined with biochemistry, molecular biology, and in vivo animal studies to develop AAV viral vectors that overcome these challenges and have improved clinical therapeutic efficacy. A key component to success is to identify regions of the capsid that participate in cellular interactions leading to or altering infection, i particular cell receptor attachment and interaction with host immunity, especially neutralizing antibodies. In this project, we will dissect the determinants of tissue transduction and also determine if these overlap with antigenic regions of the capsid. To get a general understanding we will compare AAV1/6, AAV5, AAV8, and AAV9, which represent the range of sequence and structure diversity among the AAV serotypes and have shown promise for clinical applications. We will take a reductionist approach to tackle the problem. We will first use structural biology, namely X-ray crystallography and cryo-electron microscopy and image reconstruction, to define the most antigenically reactive regions of the AAV capsids and then determine their role in infection through molecular and biochemical methods. The goal will then be to identify and mutate the residues that do not affect infection, characterize resulting vectors with respect to their antigenic reactivity against human serum, including those from post-AAV clinical gene therapy patients, and use the data arising as the guiding principle for general antibody escape AAV vector design. These will be tested in vivo, including the use of a clinically relevant hemophilia B mouse model. The overall impact of this project will be an understanding of the AAV capsid determinants necessary for successful infection and the neutralization of this process by host antibodies, a fundamental goal of virology. This information is critical for the gene therapy community in order to engineer recombinant AAV vectors for successful gene delivery in the presence of a host immune response, a natural host defense mechanism that cannot be prevented but must be circumvented in gene delivery applications because it dramatically reduces or eliminates gene expression.

Public Health Relevance

The AAV gene delivery vector system has entered an exciting phase with a number of successful human clinical trials that report therapeutic efficacy. The full realization of the translational benefits of this system will require the development of novel vectors with the capacity to retain their natural tropisms along with the ability to evade the human antibody immune response to the capsid.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
4R01GM082946-09
Application #
9066712
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Marino, Pamela
Project Start
2007-09-17
Project End
2017-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Florida
Department
Biochemistry
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Bennett, Antonette D; Wong, Kristine; Lewis, Jordyn et al. (2018) AAV6 K531 serves a dual function in selective receptor and antibody ADK6 recognition. Virology 518:369-376
Ilyas, Maria; Mietzsch, Mario; Kailasan, Shweta et al. (2018) Atomic Resolution Structures of Human Bufaviruses Determined by Cryo-Electron Microscopy. Viruses 10:
Marr, Matthew; D'Abramo, Anthony; Pittman, Nikea et al. (2018) Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene. Viruses 10:
Wang, Dan; Li, Shaoyong; Gessler, Dominic J et al. (2018) A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev 9:234-246
Pittman, Nikéa; Misseldine, Adam; Geilen, Lorena et al. (2017) Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction. Viruses 9:
Bennett, Antonette; Patel, Saajan; Mietzsch, Mario et al. (2017) Thermal Stability as a Determinant of AAV Serotype Identity. Mol Ther Methods Clin Dev 6:171-182
Mietzsch, Mario; Hering, Henrik; Hammer, Eva-Maria et al. (2017) OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA. Hum Gene Ther Methods 28:15-22
Tse, Longping Victor; Klinc, Kelli A; Madigan, Victoria J et al. (2017) Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A 114:E4812-E4821
Kondratov, Oleksandr; Marsic, Damien; Crosson, Sean M et al. (2017) Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells. Mol Ther 25:2661-2675
Mietzsch, Mario; Kailasan, Shweta; Garrison, Jamie et al. (2017) Structural Insights into Human Bocaparvoviruses. J Virol 91:

Showing the most recent 10 out of 62 publications